Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Brensocatib→

Brensocatib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1802148-05-5
Molecular formula
C23H24N4O4
Molecular weight
420.5 g/mol
Drug class
Dipeptidyl peptidase 1 (DPP1) inhibitoranti-inflammatory small molecule
Mechanism of action
Competitively and reversibly inhibits DPP1, the enzyme that activates neutrophil serine proteases during neutrophil maturation. DPP1 inhibition reduces activity of neutrophil elastase, cathepsin G and proteinase 3, which contribute to neutrophil-mediated inflammation in bronchiectasis.
Indications / reported uses
  • Treatment of non-cystic fibrosis bronchiectasis (NCFB) in adults and paediatric patients aged 12 years and older under the US FDA Brinsupri indication

Sources: NLM DailyMed — BRINSUPRI prescribing information, updated 16 Mar 2026 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Brensocatib Environmental Risk Assessment (ERA) (the Brensocatib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.